IWTI 2020 Video Series

Benefits and Challenges with Emerging Agents for Multiple Myeloma

Video Library —June 15, 2020

Categories:

Interview with the Innovators
Charise Gleason, MSN, NP-BC, AOCNP
Advanced Practice Provider Chief, Winship Cancer Institute,
Emory University,
Atlanta, GA
Kathryn Maples, PharmD, BCOP
Clinical Pharmacy Specialist, Multiple Myeloma, and PGY2 Oncology Residency Research Coordinator,
Winship Cancer Institute, Emory Healthcare,
Atlanta, GA
Chelsea Sprouse, RN-BSN, MSN, NP-C
Nurse Practitioner, Inpatient and Outpatient Malignant Hematology,
Levine Cancer Institute,
Charlotte, NC

Charise Gleason, MSN, NP-C, AOCNP, Kathryn Maples, PharmD, BCOP, and Chelsea Sprouse, FNP-C, discuss the convenience of oral therapy along with challenges in adherence to oral therapy. Additionally, they’ll discuss the tolerability of emerging drugs, the emergence of novel adverse events with new agents, and best practices in providing supportive care for patients on these novel agents.

Related Articles
Educating on HER2-Low mBC
Tajuana Bradley, MS, FNP-BC, Ryan Haumschild, PharmD, MS, MBA, Abbey J. Kaler, MS, APRN, FNP-C, Susie Ulloa, RN, OCN, ONN-CG
|
Video Library
In this inaugural video, the panel provides peer-to-peer perspectives on educating the care team and patients on the new classification of HER2-low mBC.
Fostering Shared Treatment Decision-Making
Tajuana Bradley, MS, FNP-BC, Ryan Haumschild, PharmD, MS, MBA, Abbey J. Kaler, MS, APRN, FNP-C, Susie Ulloa, RN, OCN, ONN-CG
|
Video Library
In this second installment, our expert panel suggests approaches to empowering patients to become involved in shared decision-making.
Ovarian Function Suppression in Premenopausal Breast Cancer: Are We Making Progress in Educating Patients on When to Start Therapy and the Length of Therapy?
Melissa Simon, BSN, RN, OCN, CBCN, ONN-CG, Emily Beard, RN, BSN, OCN, CBCN
|
Video Library
Hear from two breast cancer nurse navigators, Emily Beard, RN, BSN, OCN, CBCN, and Melissa Simon, BSN, RN, OCN, CBCN, ONN-CG, on the progress made in educating patients on when to start ovarian function suppression and the recommended duration of therapy.
Last modified: August 10, 2023

Subscribe Today!

To sign up for our print publication or e-newsletter, please enter your contact information below.

I'd like to receive:

  • First Name *
    Last Name *
     
     
    Profession or Role
    Primary Specialty or Disease State
    Country
SUBSCRIBE

Contact Us | Editorial Board

© 2009-2023 DBA AONN+ Academy of Oncology Nurse & Patient Navigators® PO Box 563, Cranbury, NJ 08512